In fact, the widespread occurrence of IDH1/IDH2 mutations in gliomas and acute myeloid leukemia has led to the successful development of FDA approved IDH inhibitors (Gatto et al. 2021; Tian et al. 2022), which are now used in combination therapies to treat IDH1/IDH2-positive tumors. Here, IDH1 is linked to central nervous system cancer.